Advertisement

Topics

Levosimendan Disappoints Again in Low-LVEF CABG: LICORN

06:54 EDT 10 Aug 2017 | Medscape

The inotropic agent available in much of the world was safe but didn't cut the risk of low cardiac-output syndrome in a small randomized trial, consistent with earlier trials.
Medscape Medical News

Original Article: Levosimendan Disappoints Again in Low-LVEF CABG: LICORN

NEXT ARTICLE

More From BioPortfolio on "Levosimendan Disappoints Again in Low-LVEF CABG: LICORN"

Quick Search
Advertisement